61 results about "Ethambutol" patented technology

The invention discloses ethambutol (emb) B gene mutation detection specific primers and a liquid phase chip. The liquid phase chip comprises ASPE primers, microspheres and amplification primers, wherein the specific primers of the ASPE primers are selected from SEQ ID No.18 and SEQ ID No.19 at the codon 285th site, SEQ ID No.20 and more than one of sequences from SEQ ID No.21-25 at the codon 306th site, SEQ ID No.26 and SEQ ID No.27 at the codon 330th site, SEQ ID No.28 and more than one of sequences from SEQ ID No.29-32 at the codon 406th site, and / or SEQ ID No.33 and SEQ ID No.34 at the codon 497th site. The detection result of the emb B gene mutation detection liquid phase chip provided by the invention is completely matched with that of a sequencing method, and the liquid phase chip has good signal-noise ratio.

A drug-resistance gene film chip for detecting mycobacterium tuberculosis is prepared by designing 54 probe spotting on a nylon film by aiming at the mutant sites of mycobacterium tuberculosis rpoB, kagG, embB, inhA, ahpC, gyrA, rrs, rpsL and pncA gene; 12 pairs of specific primers with biotin-labeled at 5' end are utilized; a sample DNA is subjected to triple PCR and amplified to form a large amount of gene fragment products with biotin; the amplified products and the probes on the film chip carry out specific hybridization; and then film washing, enzyme-linking and color reaction are carried out, thus preparing the chip. The gene film chip and the detection method thereof can detect the common gene mutations of the mycobacterium tuberculosis on the drug resistance of drugs such as isoniazid, rifampicin, streptomycin, ethambutol, pyrazinamide, quinolone and the like at one step, and are applicable to extracorporeal detection sputum sample, clinical isolation strains and mycobacterium tuberculosis multi-drug resistant gene in the organization sample.

The invention discloses a building method of an acute hyperuricemia renal damage mouse model. The method comprises the following steps of experiment mice are subjected to molding experiment for many days by using xanthine, ethambutol and oteracil potassium as molding agents; obtaining the acute hyperuricemia renal damage mouse model; observing the body weight, the serum uric acid level and the renal function change of the experiment mice and the kidney pathological change; the renal damage effect of the molding agent on the experiment mice is analyzed. The mice are used as model animals; the serum uric acid level of the mice is equivalent to the uric acid level of a hyperuricemia patient; the serum uric acid level is stable and can easily reappear; meanwhile, the combined effect of uric acid precursors of hypoxanthine is used; the uric acid excreted substances of ethambutol and uricase inhibitors of oteracil potassium are reduced; the acute hyperuricemia renal damage mouse model is built; the molding time is short; the model conforms to the clinical characteristics of human body hyperuricemia renal damage, and is applicable to screening hyperuricemia renal damage resisting medicine.

The invention discloses a method of extracting mycobacterium tuberculosis DNA and a kit for rapidly and accurately detecting multiple drug resistance (MDR) of mycobacterium tuberculosis. The method includes: extracting DNA to be detected from a clinical sample, determining mycobacterium tuberculosis infection by utilization of fluorescence real-time quantification PCR, indentifying whether the mycobacterium tuberculosis is drug-resistant or not and identifying the drug-resistant bacterial strain causing infection, and finally determining the pathogen infection quantity. The method can be used for detecting the whole drug-resistant genes with 29 sites that are determined to cause tubercle bacillus resistance to drugs (comprising rifampicin, isoniazide and ethambutol), and is the most comprehensive rapid molecular diagnosis system comprising tubercle bacillus drug-resistant genes so far. Through unique primers, probes and selection of fluorochrome marking designs, all the drug-resistant gene sites are detected by application of multiple qPCR. The application is simple, convenient and rapid. The results are accurate and reliable. The method and the kit have great practical value and wide application prospects for rapidly diagnosing tubercle bacillus infection and determining drug resistance, thus performing targeted treatment.

The invention discloses a preparation method of a polysaccharide-silk fibroin composite anticoagulant biomaterial. According to the process, the polysaccharide-silk fibroin composite anticoagulant biomaterial is prepared from raw materials of corn starch, Arabic gum, mannan, polyethylene carbonate, polycarbonate, silk fibroin, polydimethylsilane, triethyl phosphate, ethambutol, methane sulfonic acid and the like respectively by the steps of ultrasonic oscillation dispersion, sieving sorting, vacuum heating reaction, injection molding die-pressing, cooling fixing, ultrasonic cleaning, absorption equilibrium of an aqueous solution of positive and negative polyelectrolytes, washing and air-drying, nitrogen protection curing and the like. The prepared polysaccharide-silk fibroin composite anticoagulant biomaterial is low in raw material cost, has obvious anticoagulation and antithrombotic activity, and is suitable for application in the aspect of various medical blood pipes and accessories.

A pharmaceutical composition for treating tuberculotic diseases with no side effect / low side effect is provided by the present invention, which pharmaceutically effective amount of one or more compounds chosen from isoniazid, rifampin, pyrazinamide and ethambutol, and pharmaceutically effective amount of substances which can reduce the side effect of the antituberculosis agents.

A stabilized oral powder or granule mixture made from at least two different anti-microbial tuberculosis drugs (e.g., rifampacin, isoniazid, ethambutol, pyrazinamide), for a short-course therapy; the powder can be consumed by mixing in a glass of water or juice and assures that each of the various drugs is in fact consumed by the tuberculosis patient.

This invention relates to a process for preparing a pharmaceutical composition comprising four antitubercular drugs: rifampin or a pharmaceutically acceptable salt thereof, isoniazid or a pharmaceutically acceptable salt thereof, pyrazinamide or a pharmaceutically acceptable salt thereof and ethambutol or a pharmaceutically acceptable salt thereof, wherein rifampin and isoniazid are in separate layers. The invention also provides a pharmaceutical composition prepared therefrom having advantageous stability and bioavailability.

The present invention is gastrosis treating Chinese medicine powder and its usage. The Chinese medicine powder is prepared with notoginseng in 3 weight portions, bletilla tuber in 4 weight portions, cuttlebone in 3 weight portions and egg shell powder in 2 weight portions, and through crushing cuttlebone and frying to yellow, crushing egg shell and frying to yellow, mixing the four kinds of medicine material, grinding and sieving in 200 mesh. It is used in treating gastrosis and pulmonary tuberculosis, and has high curative effect. During treating gastrosis, the mixture of the Chinese medicine powder and powdered Western medicine metronidazole and tetracycline is taken after meal. During treating pulmonary tuberculosis, the mixture of the Chinese medicine powder and powdered Western medicine ethambutol is taken after meal.

A pharmaceutical composition includes erythromycin A or a derivative thereof and alginic acid. The alginic acid provides taste masking of the erythromycin A or derivative. The erythromycin A derivative may be clarithromycin and the alginic acid may be one or both of alginic acid and its salt. The salt may be one or more of sodium alginate and calcium alginate. The pharmaceutical composition may further include one or more of a binder, a disintegrant, a flavoring agent, and a coating. The pharmaceutical composition also may include one or more active ingredients, including omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir. The erythromycin A or a derivative thereof and the one or more active ingredients may be combined in a single pharmaceutical composition.

The invention relates to the field of natural medicaments, in particular to application of a philippine violet herb total phenol extract to treatment of hyperuricacidemia. Pharmacological tests prove that joint swelling of gouty arthritis of rats due to sodium urate crystals can be relieved obviously and the tread treatment of the rats can be improved by intragastric administration of the philippine violet herb total phenol extract. The philippine violet herb total phenol extract has the obvious inhibitory effect on hyperuricemia and urate nephropathy of mice due to a uricase inhibitor, adenine and ethambutol, but does not exert obvious influence on urinary volume, so the philippine violet herb total phenol extract has the effect of promoting the excretion of uric acid and has no effect of diuresis; and due to the single function of the philippine violet herb total phenol extract, doctors do not need to consider the influence of diuretic factors on patients during clinical application.

The invention discloses a method for simultaneously detecting five anti-tuberculosis drugs (including rifampin, rifabutin, Pyrazinamide, ethambutol and isoniazid) in blood plasma via a UPLC-MS / MS method. Blank blood plasma is weighed precisely, and added with standard working solutions mixed with a series of standard substances, standard working solutions of isotope internal standards in one to one correspondence are added, pre-treatment is carried out in a protein precipitation method, the UPLC-MS / MS method is used for analysis, chromatograms of different samples are obtained, and a standardcurve is established by taking the ratio of an object to be measured and the corresponding internal standard peak area as the abscissa and the concentration of the object to be measured as the ordinate; and blood plasma to be measured is weighed precisely, the standard working solutions of isotope internal standards in one to one correspondence are added, pre-treatment is carried out in the protein precipitation method, the UPLC-MS / MS method is used for analysis, chromatograms of different samples are obtained, and the concentration of the blood plasma sample is calculated by using the standard curve. The method is simple and rapid in operation and high in sensitivity, accuracy and precision, the matrix effect is low, and can satisfy requirements for monitoring the drug concentration of five anti-tuberculosis drugs in clinical application.

The invention discloses a method for detecting an anti-tuberculosis drug in serum by an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The antitubercular drug comprises cycloserine (CYS), pyrazinamide (PZN), isoniazid (INZ), p-aminosalicylic acid (P-ASA), ethiisonicotinamide (ETN), ethambutol (ETB), clofazimine (CFM), bedaquiline (BDQ), rifampicin (RFP), rifbutine (RFB) and rifapentine (RFT). The method includes: detecting the content of the antituberculosis drug in the pretreated serum by adopting an ultra-high performance liquid chromatography-tandem mass spectrometry method, performing quantifying by utilizing a mass spectrometry isotope internal standard method, establishing a calibration curve by taking the concentration ratio of the standard substance to the internal standard substance as an X axis and the peak area ratio of the standard substance to the internal standard substance as a Y axis, and calculating the concentration of the target drug in the serum; the method is high in sensitivity, strong in specificity and simple in pretreatment process, separation and detection of the anti-tuberculosis drugs in serum are completed within 5 min, and a simple and rapid detection method is provided for clinical concentration monitoring of the anti-tuberculosis drugs.

The invention discloses a construction method and application of a recombinant drug-resistant BCG strain, M.bovis BCG is used as an original bacterium to construct a drug-resistant BCG strain with resistance to at least one of streptomycin, levofloxacin, ethambutol, protionamide, p-aminosalicylic acid and amikacin; and sequence fragments capable of expressing related antigens Ag85b and Rv2628 causing immune response can be further inserted to construct a recombinant drug-resistant BCG strain. The recombinant drug-resistant BCG strain can compete with Mtb in growth to accelerate death of the Mtb, and when the recombinant drug-resistant BCG strain is combined with a drug for treating tuberculosis, the treatment effect on Mtb (sensitive Mtb and drug-resistant Mtb) can be further enhanced, re-infection of a patient can be avoided, and an important medical prospect is achieved.

The present invention discloses one kind of Chinese medicine powder for treating tuberculosis and its treating method via combination with Western medicines. The Chinese medicine powder consists of bletilla tuber, notoginseng, gallnut and pangolin scales, and is orally taken together with Western medicines isoniazid, ethambutol, metronidazole and vitamin B6. It is taken with pork stomach and lung soup or pork trotter soup. It has high curative effect, short treatment period, and other advantages, and may be industrial produced.

The invention particularly provides a kit and a method for detecting antituberculous drugs and metabolites thereof in a sample. The kit is used for detecting antituberculous drugs and metabolites thereof in a sample, and comprises a calibration product, a quality control product, an instrument quality control product and an isotope internal standard product, both the calibration material and the quality control material contain rifampicin, isoniazide, rifapentine, pyrazinamide, ethambutol, clofazimine, cycloserine, moxifloxacin, levofloxacin, linezolid, acetyl isoniazide, bedaquiline and deacetylrifampicin; the instrument quality control product comprises a methanol solution containing rifampicin, isoniazid, rifapentine, pyrazinamide, ethambutol, clofazimine, cycloserine, moxifloxacin, levofloxacin, linezolid, acetyl isoniazid, bedaquiline and deacetylrifampicin; the isotope internal standard substance contains an internal standard substance corresponding to a substance contained in the calibrator. The kit disclosed by the invention can be used for detecting the concentrations of the antituberculous drugs and metabolites thereof in various sample types.

The invention discloses a method and device for constructing an animal model suffering from diabetes induced by the high uric acid content. The method comprise the steps of 1, conducting the following operation at the first stage, wherein a target animal is fed with ordinary high-fat feed, one or more times of gavage is conducted on the target animal with an adenine aqueous solution, and one or more times of subcutaneous injection is conducted on the target animal with an ethambutol aqueous solution; 2, conducting the following operation at the second stage, wherein the target animal is fed with ordinary high-fat feed, gavage is conducted on the target animal with an adenine aqueous solution, and subcutaneous injection is conducted on the target animal with an ethambutol aqueous solution. The first modeling stage lasts for 5-7 weeks, and the second modeling stage lasts for 7-9 weeks.

The invention discloses a formula of a pharmaceutical composition for treating pulmonary tuberculosis in the technical field of medicine. The formula contains the following major components: 0.3-0.5 g of isoniazid; 0.38-0.58 g of rifampin; 0.75-0.95 g of pyrazine amide; 0.6-0.8 g of streptomycin; 1.2-1.4 g of ethambutol; 0.45-0.65 g of aminosalicylic acid; and 2.5-4.5 g of tryptophan. The invention also provides a preparation method of a pharmaceutical composition for treating pulmonary tuberculosis, which specifically comprises the following steps: S1, adding water for injection to a container; S2, sequentially adding combination drugs; S3, adding tryptophan and uniformly stirring; S4, adding a stabilizer and adjusting the pH value of the solution; S5, adding activated carbon; and S6, performing high-temperature sterilization of subpackaging. According to the invention, the tryptophan is added, which can alleviate the discomfort of a tuberculosis patient caused by side effects of the medicine; the cooperative use of aminosalicylic acid, isoniazid and rifampin can delay the generation of drug tolerance of a tuberculosis patient. The preparation method is simple in operation and suitable for large-batch production.

The invention discloses a method for preparing a rubber plastic foaming thermal-insulation material by utilizing a waste rubber product. The method comprises the following steps: adding the waste rubber product, chlorinated polyethylene, benzoyl peroxide and ethambutol into an internal mixer and internally mixing for 10-15min; adding 1,4-ditert-butyl peroxide isopropyl benzene and triallyl isocyanurate and performing smelting reaction for 5-10min; continuously raising temperature to 120-130 DEG C and then adding expandable microsphere, kieselguhr and nanometer calcium carbonate and foaming for 10-15min; continuously raising temperature to 150-160 DEG C, adding azodicarbonamide and mica powder and foaming for 8-10min; and cooling the reaction and then drying, thereby acquiring the rubber plastic foaming thermal-insulation material.

Healthcare costs are a significant worldwide, with many patients being denied medications because of their high prices. One approach to addressing this problem involves the biosynthesis of chiral drug intermediates, an environmentally friendly solution that can be used to generate pharmaceuticals at much lower costs than conventional techniques. In this context, embodiments of the invention comprise methods and materials designed to allow microorganisms to biosynthesize the nonnatural amino acid L-homoalanine. As is known in the art, L-homoalanine is a chiral precursor of a variety of pharmaceutically valuable compounds including the anticonvulsant medications levetiracetam (sold under the trade name Keppra®) and brivaracetam, as well as ethambutol, a bacteriostatic antimycobacterial drug used to treat tuberculosis. Consequently, embodiments of the invention can be used in low cost, environmentally friendly processes to generate these and other valuable compounds.

The invention provides a mycobacterium tuberculosis drug resistance detection related nucleic acid fragment combination of four first-line drugs including rifampin, isoniazid, streptomycin and ethambutol for tuberculosis, and an application thereof. Specifically, the invention provides a mutated nucleic acid fragment combination of rifampin drug resistance-related gene rpoB, isoniazid drug resistance-related gene katG, inhA promoter and ahpC promoter, streptomycin drug resistance-related genes rpsL and rrs, and ethambutol drug resistance-related gene embB, oligonucleotide for specifically detecting mutation, a kit prepared from the oligonucleotide, and related drug resistance detection methods.

The invention discloses a pyrosequencing-based method for detecting tolerance of mycobacterium tuberculosis ethambutol. The method comprises the following steps: 1, carrying out polymerase chain reaction (PCR) amplification on an embB gene; designing a PCR amplification primer aiming at 306 sites of the embB gene; taking a sample mycobacterium tuberculosis deoxyribonucleic acid (DNA) extract as a template, and carrying out PCR amplification on the embB gene containing the 306 sites of the embB gene, wherein the length of a DNA segment for amplifying the mycobacterium tuberculosis embB gene is 165bp, and the sequence containing the 306 sites of the embB gene is atg; 2, carrying out pyrosequencing on the PCR amplification product, judging whether the 306 sites of the embB gene have mutation or not, wherein the pyrosequencing adopts a supplier quality assurance (SQA) mode, and the nucleotide loading order is AGCT. By check for a plurality of times, the drug-resistant mutation site of ethambutol embB gene can be accurately detected by a test primer of the shown sequence, the drug-resistant strains of the mycobacterium tuberculosis can be quickly screened, and early detection, early diagnosis and early treatment of a sufferer infected with the drug-resistant mycobacterium tuberculosis are achieved.

A pharmaceutical composition includes erythromycin A or a derivative thereof and alginic acid. The alginic acid provides taste masking of the erythromycin A or derivative. The erythromycin A derivative may be clarithromycin and the alginic acid may be one or both of alginic acid and its salt. The salt may be one or more of sodium alginate and calcium alginate. The pharmaceutical composition may further include one or more of a binder, a disintegrant, a flavoring agent, and a coating. The pharmaceutical composition also may include one or more active ingredients, including omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir. The erythromycin A or a derivative thereof and the one or more active ingredients may be combined in a single pharmaceutical composition.

The invention discloses an LC-MS / MS method for quantitatively analyzing the plasma concentration of an antituberculous drug. The method can simultaneously detect isoniazide, rifampicin, pyrazinamide and ethambutol through S1 standard working solution preparation, S2 sample preparation, S3 sample treatment, S4 sample detection and S5 standard curve making and quantitative analysis, the sample pretreatment process is simple and is easy to operate, and all the reagents are conventional reagents, so that the cost is lower. According to the method, a reversed-phase C18 column of 150 mm*2.1 mm is adopted, the flow rate is controlled to be 0.3 mL / min, and the column temperature is 30 DEG C; the problem that the polarity difference of isoniazide, rifampicin, pyrazinamide and ethambutol is large can be well solved, the separation effect is better, and the cost is lower. The method has the advantages of higher sensitivity, accuracy and precision, wide detection linear range and short detection time, and can be used as a reliable detection method suitable for popularization and for monitoring the treatment concentration of clinical first-line anti-tuberculosis drugs.

The invention discloses a method for detecting five anti-tuberculosis drugs (including rifampicin, rifabutin, pyrazinamide, ethambutol and isoniazid) in blood plasma by UPLC-MS / MS. First, accurately measure blank plasma, add a series of mixed standard standard working solutions, and add one-to-one corresponding isotope internal standard standard working solutions. After pretreatment by protein precipitation, use UPLC-MS / MS for analysis to obtain each sample. For the chromatogram, take the peak area ratio of the analyte and its corresponding internal standard as the abscissa, and use the concentration of the analyte as the ordinate to establish a standard curve; then accurately measure the plasma to be tested, and then add a one-to-one corresponding isotope internal standard standard The sample working solution was pretreated by the protein precipitation method, and analyzed by UPLC-MS / MS to obtain the chromatograms of each sample, and the concentration of the plasma sample was calculated using the standard curve. The method is simple and quick to operate, has high sensitivity, accuracy and precision, and has little matrix effect, and can meet the needs of drug concentration monitoring of five anti-tuberculosis drugs in clinical application.

The present invention relates to a monolayer tablet for use in the treatment of tuberculosis comprising a mixture of: granules comprising isoniazid, pyrazinamide, ethambutol or a pharmaceutically acceptable salt thereof and at least one granulation binder, rifampicin in powder form, extragranular excipients, wherein all of the granules have a particle size that is less than 0.599 mm, preferably less than 0.5 mm, more preferably less than 0.422 mm, and to its process of preparation.

The invention provides molecular beacon probes for rapidly assaying ethambutol-resistant mycobacterium tuberculosis. The molecular beacon probes include Beacon EMB1, Beacon EMB2 and Beacon EMB3. By means of the signal synergy of the three molecular beacon probes, with the embABC gene of mycobacterium tuberculosis as a target spot, ethambutol-resistant mycobacterium tuberculosis is assayed. The probes in the invention have high fluorescence intensity and high specificity, and can effectively and rapidly assay ethambutol-resistant mycobacterium tuberculosis. The invention also discloses a kit and an assay method for rapidly assaying ethambutol-resistant mycobacterium tuberculosis.

The invention discloses a mycobacterium tuberculosis EmbB mutant gene and an application thereof. Compared with the common EmbB gene, the mutant gene has the c.233A>G mutation site. According to the invention, by utilizing the candidate gene screening method, 18 Chinese ethambutol-resisting tuberculosis strains are detected, the gene mutation site is found for the first time, and in the ethambutol-resisting tuberculosis strains, EmbB gene mutation c. 233A>G has certain frequency of occurrence, and therefore, the EmbB gene mutation c. 233A>G can be taken as the diagnostic basis for the drug-resisting molecular mechanism of the ethambutol-resisting strains in clinic.

The invention discloses application of tranilast-combined anti-tuberculosis medicaments in preparation of a medicament for treating tuberculosis, and at least two of the tranilast-combined anti-tuberculosis medicaments (isonicotinyl hydrazine, rifampicin, pyrazinoic acid amide and ethambutol) are adopted. After the medicament combination is applied for 50 days, a patient can feel that skin damage is obviously alleviated; after the medicament combination is applied for 3 to 4 months, skin damage of the patient almost completely disappears with a speed obviously greater than that of a control group of pure anti-tuberculosis treatment, so that the anti-tuberculosis treatment course is greatly shortened, tissue damage such as atrophic scar formation and pigmentation can be reduced, and no obvious adverse reaction exists, which indicates that the tranilast-combined classical anti-tuberculosis medicaments have a synergistic anti-tuberculosis effect, are capable of obviously shortening the anti-tuberculosis treatment course and enhancing the anti-tuberculosis curative effect when used for resisting the tuberculosis, are good in toleration and relatively high in compliance of patients, free from obvious adverse reaction, and relatively good in clinical curative effect and security, and are expected to become necessary medicaments for combined treatment of the tuberculosis.